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ABSTRACT 
 
Chronic hyperinsulinemia associated with insulin resistance is directly and indirectly associated with many 
metabolic disorders that contribute to significant morbidity and mortality. Because hyperinsulinemia is not widely 
recognised as an independent health risk, there are few studies that assess management strategies.  Medication 
management may not address the multiple issues associated with hyperinsulinemia.  Lifestyle management 
includes physical activity, especially high intensity interval training, and dietary management.  Reducing 
carbohydrate quantity and increasing nutrient density are discussed with carbohydrate-restricted and Mediterranean 
diets conferring additional benefits to a low-fat diet.    Physical activity and dietary management provide the 
foundation for hyperinsulinemia management and may work synergistically.  Of these principles, a combination of 
resistance and high intensity interval training, and carbohydrate restriction provide the two most effective frontline 
management strategies for managing hyperinsulinemia. 
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Introduction 
Compensatory hyperinsulinemia (further 
referred to as "hyperinsulinemia") is associated, 
mechanistically and epidemiologically, with many 
chronic metabolic diseases.1, 2 The aetiology of 
hyperinsulinemia is likely heterogeneous2 and in the 
earliest stages asymptomatic.3 Early management of 
hyperinsulinemia may prevent, delay, or mitigate the 
severity of subsequent pathologies.  Although 
hyperinsulinemia is a common co-pathology with 
impaired glycemic control, this paper focuses on the 
management of hyperinsulinemia in the presence of 
normal glucose tolerance.   
There are several different states that depict 
the continuum that reflects healthy insulin response 
through to hyperinsulinemia. It is proposed that 
people transition between different states, which may 
be either acute or chronic, depending on the 
circumstances at the time, and may be subject to 
change. The close relationship between the two 
different states of hyperinsulinemia and insulin 
resistance can also be noted. This means that as well as 
targeting insulin levels directly, strategies that improve 
insulin sensitivity, especially the up-regulation of 
glucose transporter type 4 (GLUT4), will also reduce 
hyperinsulinemia. As there are few studies that directly 
assess hyperinsulinemia management strategies, this 
review will include strategies that improve glycemic 
control in the absence of evidence of increased insulin 
secretion. It will also consider strategies that provide 
symptomatic improvement of conditions associated 
with hyperinsulinemia such as polycystic ovarian 
syndrome (PCOS).  
There are two main strategies for managing 
hyperinsulinemia:  maximising insulin sensitivity and 
reducing glycemic load.  Insulin sensitivity can be 
maximised via up-regulating GLUT4 or insulin 
receptors, or by preventing (further) insulin resistance.  
Glycemic load may occur through two main pathways, 
endogenous through metabolic pathways such as 
gluconeogenesis, glycolysis, or renal reabsorption4, and 
exogenous via dietary intake. 
There are three main mechanisms to achieve 
each of these strategies: Physical activity, diet, and 
medicines and other supplements. 
 
Methodology 
Literature was reviewed on hyperinsulinemia 
and insulin resistance, targeting full-text English 
language studies. There was no date criterion. Articles 
were selected on the basis of having a minimum of 
both a plausible biological mechanism and established 
clinical association. An  academic database search 
included EBSCO, Medline and Google Scholar, using 
variants of the terms “hyperinsulinemia,” “insulin 
resistance,” “type 2 diabetes,” and “metabolic 
syndrome,” and each of these terms in conjunction 
with variants of “diet,” “nutrition,” “physical activity,” 
“pharmacology,” and “treatment.” References were 
based on the authors’ judgment of relevance, 
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completeness, and compatibility with clinical, 
epidemiological, pathological and biochemical criteria. 
 
Physical activity 
Physical activity is well-documented for 
improving insulin sensitivity. Mechanistically this 
occurs via GLUT4 up-regulation, increased 
hexokinase gene transcription5, increased fuel 
consumption and, if sustained, decreases to insulin 
secretion.6 Conversely, sustained physical activity can 
also increase glucagon, cortisol and catecholamine 
secretion.6 These hormones can all increase 
gluconeogenesis and if unbalanced, impair rather than 
improve insulin sensitivity. Very intense physical 
activity stimulates insulin production, especially in the 
presence of hyperglycemia. Without question, physical 
activity will be a key component for managing 
hyperinsulinemia, but the question remains whether 
different forms of physical activity can maximize 
sensitivity while minimizing counter-hormones.  
Physical activity can be broadly divided into 
two main classifications that have considerable 
overlap: resistance training and aerobic activity.  The 
latter has a further subset: high intensity interval 
training (HIIT). 
 
Resistance training 
Resistance training is characterized by muscles 
contracting against an external resistance causing brief 
and isolated activity of single muscle groups.7 The 
health-benefits of resistance training are well-
recognized. These can include decreases to HbA1c, 
weight, body fat, and blood pressure.8 Other 
improvements include increases to bone mineral 
density, and lean body mass. There are also potential 
benefits to mood and cognition, balance and falls-risk, 
and overall self-esteem.  
Resistance training may improve 
hyperinsulinemia through three main mechanisms: 
increasing, or maintaining muscle mass, glucose 
expenditure and enhancing the cellular metabolic 
capacity. It is estimated that inactive adults lose 3-8% 
of muscle mass per decade accompanied by a 
reduction in resting metabolic rate8 Losing muscle 
mass means that glucose disposal will be harder 
resulting in increased adiposity. Increased muscle mass 
is posited as one explanation for the improvements in 
glucose disposal rates for resistance training.9 This is 
because both weight lifters and long-distance runners 
show increased glucose disposal rates compared to 
controls; however, this difference remains only for the 
long-distance runners after differences in lean-body-
mass are taken into account. This is consistent with 
other studies comparing aerobic to resistance training, 
which only showed improvements in glucose disposal 
when the results were expressed per kilo of fat-free-
mass. 
While resistance training is believed to 
enhance cellular metabolic capacity by mechanisms 
such as GLUT4 mobilization9, potentially negative 
effects by way of increased cortisol are also observed.  
Crucially, fewer repetitions and longer rest periods 
between sets elicit a lower cortisol response, which 
may be important for beginners to resistance 
training.10 Increased catecholamine and/or insulin 
secretion may also be observed with resistance 
training. These changes may also be exercise-dose 
dependent and may attenuate as training adaptation 
occurs. An elevated insulin response is associated with 
protein/carbohydrate supplementation. Elevated 
hormonal responses may also be associated with 
overtraining.10 
 
Aerobic exercise   
Aerobic exercise can be broadly described as 
light to moderate intensity activities that can be 
performed for extended periods of time. Examples of 
aerobic exercise include walking, jogging and 
swimming. There is a large body of literature on the 
type and amount of aerobic activity required to 
maintain health. Conventional wisdom suggests that a 
minimum of 30 accumulated minutes of moderate 
intensity activity (ie. brisk walking) should occur on 
most days to achieve health benefits11, although the 
efficacy of this volume has since been questioned.12 
Aerobic exercise is believed to improve metabolic 
health via the same mechanisms as resistance training.   
A meta-analysis comparing resistance training 
to aerobic exercise concluded that clinically, there were 
no advantages between resistance training and aerobic 
exercise for lowering HbA1c or impacting 
cardiovascular risk.7 However, aerobic exercise was 
modestly advantageous for lowering BMI. Resistance 
training may confer greater benefit to those with 
limited mobility as many of the exercises can be 
performed by the sedentary. 
 
High intensity interval training (HIIT)   
HIIT protocols are a subset of aerobic 
exercise characterized by short, maximal-intensity, 
anaerobic exercise sessions separated by medium or 
low intensity periods for recovery.  There are several 
advantages to HIIT protocols compared to 
conventional aerobic exercise: time; glucose utilization 
and cellular metabolic capacity.  Lack of time is the 
biggest reason cited for not exercising.9 HIIT 
protocols allow for greater power output for an 
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equivalent amount of energy expenditure but in a 
shorter period of time13 resulting in greater 
improvements to cardiorespiratory fitness.14 Other 
benefits of HIIT compared to conventional aerobic 
training include greater reductions of skinfold 
thickness and decreased AUCinsulin.15, 16 HIIT protocols 
may have further advantages over traditional aerobic 
exercise regimes as they can be used safely and 
effectively in people following cardiac stenting, 
coronary artery grafting and myocardial infarction. 
Musculoskeletal injuries were no more common than 
that found with other forms of exercise.14, 17-19 These 
results demonstrate that HIIT is safe and effective 
when performed under controlled conditions.  
Patients new to HIIT may require specific assessment 
and/or instructions from an exercise physiologist or 
physiotherapist. 
GLUT4 adaptation can occur with single 
bouts of exercise and effects persist for up to 40 
hours.20, 21 This suggests that, especially in the early 
days of adopting physical activity, varying the activities 
undertaken may maximize GLUT4 adaptation while 
minimizing effects from over-secretion of cortisol or 
glucagon. While the literature suggests the ideal 
activity should comprise a combination of resistance 
training and HITT protocols, the final selection of 
physical activities may be influenced by personal 
circumstances, including preference, health status and 
levels of training required. 
 
Diet 
There is considerable public and scientific 
debate and discussion concerning the optimal dietary 
approach for the management of metabolic 
dysregulation.  Without discussing macronutrient 
proportions, it is generally agreed that a healthy diet 
should predominantly be comprised of the following:  
1. whole foods22, 2. adequate protein and other 
currently established essential nutrients including 
water, specific vitamins, minerals, electrolytes and fatty 
acids23, 3. adequate energy, 4. aequate fiber, although 
fiber may not be considered aequate, there is sufficient 
evidence to support its inclusion.24-26 A diet that limits 
the risk of, or manages the effects of, hyperinsulinemia 
should also consider the following: 5. prevents acute 
hyperglycemia, whether via either exogenous 
carbohydrate or gluconeogenesis, thus preventing 
acute hyperinsulinemia, 6. prevents caloric overload, 
thus limiting both the amount of energy to be stored 
as fat and the potential for hyperglycemia, 7. limits 
items known to down-regulate GLUT4 or insulin 
receptors (e.g. arachidonic acid), 8. promotes items 
known to up-regulate GLUT4 or insulin receptors and 
finally 9. causes sufficient satiety so that hormones, 
receptors and transporters are not over stimulated.  
Adherence factors, including adverse 
reactions should also be considerations.  Adherence is 
recognized as being key to weight-loss.27 Traditionally, 
obesity is seen as the driver of many metabolic 
diseases, so weight-loss is the first step to improved 
health.28 However, the metabolic theory of disease 
states that metabolic changes including 
hyperinsulinemia may precede weight gain.  Under this 
model, weight-gain is the first visible symptom of 
metabolic disease, therefore weight-loss should also 
indicate health improvements.  This means that dietary 
adherence will also be associated with improvements 
to hyperinsulinemia.   
Dietary research is complicated as many 
studies use “standard” diets as the control.  This 
“standard” diet is generally low in fruits and vegetables 
and high in sugars and refined carbohydrates.29 As this 
diet will likely be lacking in essential nutrients and 
fiber, cause acute hyperglycemia, and have excessive 
calories, any dietary regime that reverses these trends 
will show improvements to health.  Furthermore, diet-
health research often employs weight loss as the 
primary end-point, rather than other metabolic 
markers, yet improvements to metabolic markers are 
possible without significant weight changes.30 
However, any dietary approach that causes weight 
loss, will improve hyperinsulinemia as body fat can 
only be stored, rather than oxidized in the presence of 
high insulin levels.31  Therefore both improved 
glycemic control and weight loss can be used as 
proxies for improved hyperinsulinemia.  
There are three distinct dietary approaches 
(low fat; Mediterranean; and carbohydrate-restricted) 
that are shown to improve glycemic control.  
Improved glycemic control may indicate improved 
insulin response, so these diets should be considered 
for managing hyperinsulinemia.  Although there is 
some evidence to support high protein diets for the 
treatment of diabetes, excess protein will induce 
gluconeogenesis, thus breaching criterion 4.  
Therefore, only moderate protein diets will be 
considered in this review.  As few studies directly 
target hyperinsulinemia, the question remains are any 
of these three approaches superior to the others for 
managing hyperinsulinemia?   
 
Low-fat 
Currently, the low fat, high carbohydrate dietary 
approach is considered to be standard practice for 
managing diabetes by many authorities.  For adults 
(aged 19 and older) this regime generally comprises 
20-35% fat, (< 10% saturated fats), 10-35% protein 
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and 45-65% carbohydrate.32 Fruits, vegetables and 
whole-grains are recommended as carbohydrate and 
fiber sources, while vegetable oils (excluding coconut, 
palm and palm kernel oils) are emphasized as healthy 
fat sources.29 Lean protein, including fat-free or low-
fat dairy products, or vegetable protein sources, are 
also recommended. 
 
Mediterranean  
Although there are a variety of  
“Mediterranean” dietary approaches33, the term 
generally defines a diet that comprises a high amount 
of monounsaturated fatty acids (MUFA), 
predominantly from olive oil (35%), fruits and 
vegetables, whole-grains and fish; moderate amounts 
of alcohol and small amounts of red meat, sugars and 
refined grains.34, 35 
    
Carbohydrate-restriction 
Like the Mediterranean diet, there is no clear 
definition of a carbohydrate-restricted diet.  Daily 
carbohydrate intake has been defined as 12-40% of 
daily energy intake or < 20 -150g/day (36-39).   To 
ensure adequate energy, the fat content of the diet is 
increased, up to about 75% of daily energy content. 
   
Comparison of different dietary strategies 
Each of these diets have notable benefits for 
the management of diabetes compared to standard 
diets.40-42 It is traditionally considered that weight 
management is the key driver behind metabolic 
improvements, hence the previous favour of the low-
fat (and consequently low-calorie) diet.  However, 
emerging research suggests that increased benefits to 
metabolic health can be found from diets higher in 
fats and lower in carbohydrates.  A meta-analysis 
compared Mediterranean diets to low-fat diets in 
overweight/obese people (n = 2650, 50% female) over 
two years of follow-up.  Those following the 
Mediterranean diet had greater improvements to body 
weight and BMI, systolic and diastolic blood pressure, 
fasting glucose, total cholesterol, and high-sensitivity 
C-reactive protein (hs-CRP).35 While some of the 
effects were modest, the weighted mean differences 
clearly favoured the Mediterranean diet.  This suggests 
that low-fat diets may not be optimal for managing 
diabetes, or hyperinsulinemia.    
Although this study does not directly assess 
hyperinsulinemia, the improvements to the other 
metabolic markers, especially fasting glucose, imply 
improvements to hyperinsulinemia.  There are several 
potential mechanisms for these observations.  Firstly, 
the lower carbohydrate content and therefore glycemic 
load means that acute hyperglycemia, and hence acute 
hyperinsulinemia is less likely.43.  Fewer glucose 
molecules to be absorbed into the cells reduces 
metabolic stress.  MUFA are believed to enhance 
insulin signaling44 whereas using omega-6 rich 
polyunsaturated oils may lead to an increase in 
arachidonic acid, which may down regulate GLUT4.45  
The Mediterranean diet is also associated with 
a high degree of satiety.46 Satiety may help to prevent 
overeating and allow longer periods of fasting.  
Restricting carbohydrates have also been shown to 
confer additional health benefits compared to low-fat 
diets, especially with respect to weight, lipid profile, 
glycemic control, and potentially kidney function.47-50  
There are few large studies that compared the effects 
of carbohydrate restricted diets to the Mediterranean 
diet.  However, restricting carbohydrates conferred 
greater weight loss, a larger decrease in triglycerides 
and hsCRP, and larger increase to HDL after six 
months of dietary intervention.36 The Mediterranean 
diet favored a decrease in fasting glucose in people 
with diabetes.  The differences between the two diets 
had narrowed by 24 months but both showed 
improvements compared to a low-fat diet.   
A key hyperinsulinemia management strategy 
is to prevent hyperglycemia and insulin secretion.  This 
may explain the additional benefits to carbohydrate 
restriction.  There are concerns regarding carbohydrate 
restriction, predominantly concerning high dietary fat.  
High fat consumption, especially saturated fats, is 
traditionally associated with adverse metabolic 
outcomes.  However, studies conducted over two 
years have not found additional health risks.51  
Furthermore, high-fat dairy has been found to 
decrease the incidence of type 2 diabetes and the risk 
of death or hospitalization due to coronary heart 
disease, compared to low-fat dairy.52, 53 It is now 
believed that there are sub types of saturated fats 
which have different health effects.54   
Hyperinsulinemia encompasses a range of 
severities.  All three dietary strategies discussed above 
have the potential to improve the disorder.  Logically, 
carbohydrate consumption in excess of what the body 
can tolerate, will invoke excessive insulin secretion.  
Therefore restricting carbohydrates to a tolerated level 
should confer maximal health benefit, especially if the 
person consumes a whole-food diet based on 
Mediterranean principles.  However, effective dietary 
management may be governed by adherence to the 
chosen regime.27, 55  
  
Isolated beneficial nutrients / foods 
Other compounds that have been shown to 
improve glycemic control include magnesium, 
chromium, garlic, cinnamon, and green tea.   
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Figure 1: Glucose and insulin response curves following an oral glucose tolerance test in a patient with type 2 diabetes on 
insulin who inadvertently injected her normal morning insulin prior to the test.  Data reproduced from Kraft77  
 
Magnesium is believed to improve GLUT4 
expression in rodent studies independently to insulin 
action.56 Chromium may improve insulin receptor 
sensitivity.57 There is some evidence to suggest many 
people are chromium deficient, especially if they eat 
highly refined foods, which, are not only unlikely to 
contain sufficient chromium, can also exacerbate its 
loss.58 Emerging evidence suggests that magnesium 
and chromium may work synergistically to improve 
glycemic control.59 Foods rich in these minerals are key 
components of the Mediterranean diet, especially nuts 
and whole grains.  Green tea supplements, garlic and 
cinnamon60-62 may also be beneficial improving insulin 
sensitivity, but the mechanisms are not fully 
elucidated.   
There are a number of traditional remedies 
for treating type 2 diabetes that may be beneficial for 
managing hyperinsulinemia including (but not limited 
to) berberine63, 64, fenugreek65, 66, bilberries67, and black 
cumin.68, 69 While the mechanism of actions of these 
products are not fully elucidated, they are posited to 
include 5' adenosine monophosphate-activated protein 
kinase (AMPK), (berberine) similar to that of 
metformin70 or preventing carbohydrate absorption 
(bilberries, fenugreek).  It is necessary to further assess 
the effect of these remedies on insulin release as both 
berberine and black cumin are posited to increase 
insulin release, although reports are mixed.  
 
 Medications 
As previously stated, this review is 
predominantly concerned with hyperinsulinemia in the 
presence of normal glucose tolerance.  However, as 
people with impaired glycemic control, are likely to be 
hyperinsulinemic3 plausibly, strategies that improve 
glycemic control without aggravating hyperinsulinemia 
may optimize health.    Other medications that affect 
hyperinsulinemia may not be prescribed for metabolic 
disease; however, understanding this adverse effect is 
important.   
There are two main medication strategies for 
managing hyperinsulinemia:  eliminating those that 
aggravate insulin resistance or contribute directly to 
hyperinsulinemia; and prescribing medications that 
improve insulin sensitivity.  The latter should be 
considered second-line to lifestyle management.  
Medication management will be limited especially if 
hyperglycemia, or other clinical conditions, need to be 
considered.  For example, both antipsychotic 
medications, and longer courses of prednisone are 
known to aggravate insulin resistance and increase the 
risk of developing type 2 diabetes.71   However, 
stopping these medications in many patients may be 
inappropriate so alternative strategies need to be 
considered.  
  
Medications that theoretically worsen 
hyperinsulinemia  
Medications may induce hyperinsulinemia by: 
GLUT4 down-regulation; hyperglycemia (via increased 
appetite, or affecting hormones such as adrenaline or 
cortisol); or directly increasing insulin secretion.  
These properties, especially GLUT4 down-regulation, 
may be difficult to discern from medication data 
sheets.  If listed side-effects include weight gain or an 
increased risk of developing type 2 diabetes, then 
hyperinsulinemia should be a reasonable suspicion.   
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 Improved by  Worsened by Indeterminate 
Insulin receptor 
availability 
Time 
Chromium 
MUFA 
 
Hyperglycemia 
Hyperinsulinemia 
Cortisol 
Highly refined foods 
 
 GLUT4 up regulation 
Magnesium 
Metformin 
Physical activity 
Time 
 
Excessive physical 
activity 
Arachidonic acid 
 
 
Hyperglycemia 
Carbohydrate-restricted diets 
Mediterranean diet 
Physical activity 
Black cumin 
Excessive physical 
activity 
Excessive protein 
Excessive carbohydrate 
 
High-carbohydrate, Low fat 
diets 
Hyperinsulinemia   
Insulin 
Insulin secretagogues 
Insulin mimetics 
Very intense physical 
activity 
Excessive protein 
Excessive carbohydrate 
Berberine 
Black cumin 
 
AMPK activation 
 
Berberine  
 
Reduced carbohydrate 
absorption 
Carbohydrate-restricted diets 
Bilberries 
Fenugreek 
 
Excessive dietary  
carbohydrate 
 
Mechanism unknown 
Green tea 
Garlic 
Cinnamon 
 
 
 
Table 1: Summary of management strategies for managing hyperinsulinemia 
 
 
Medications known to down regulate GLUT4 include: 
clozapine72; ritonavir73; statins74; and corticosteroids.75 
Plasma insulin is increased by exogenous 
insulin, insulin secretagogues, or insulin mimetics, 
prescribed to manage hyperglycemia.  Although the 
insulin secretagogues such as sulphonylureas are less 
commonly used.76, little is known about the effects of 
these medications on hyperinsulinemia.  An 
unpublished case report suggests exogenous insulin 
used in type 2 diabetes can produce insulin spikes > 
400 µU/mL for a number of hours following a 100g 
glucose load77 as shown in Figure 1.  The maximal 
insulin concentration remains unknown as the 
reference standard was only calibrated to a maximum 
of 400 µU/mL.   
Despite this degree of serum insulin elevation, 
it can be noted that the patient did not attain a normal 
glycemic profile.  The combination of hyperglycemia 
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and hyperinsulinemia increases the risk of a poor long-
term prognosis for this patient.  Further research is 
required to establish if this is an isolated situation or 
the standard response for many patients with type 2 
diabetes. 
 
Medications potentially beneficial for 
hyperinsulinemia 
Although the somatostatin analogue, 
octreotide, is used to treat isolated hyperinsulinemia, 
(e.g. insulinoma)78, 79, compensatory hyperinsulinemia 
cannot be managed without concurrent glycemic 
control.  Hyperglycemia is well recognized to have 
adverse pathologies, including diabetic ketoacidosis.  
But ketoacidosis can be triggered by low insulin levels 
independent of glycemic status. Increasing levels of 
glucagon and cortisol may be triggered by cellular 
starvation, or hypoglycemia.  These hormones can 
induce gluconeogenesis and glycogenolysis leading to 
overproduction of the ketone bodies acetoacetic acid, 
β-hydroxybutyrate and acetone.80 Both acetoacetic acid 
and β-hydroxybutyrate are strong acids.  Under normal 
circumstances insulin levels help to regulate the 
production of these ketone bodies, but in its absence 
potentially fatal ketoacidosis may develop.   
Thiazolidinedione-type insulin sensitizers, 
such as rosiglitazone, improve peripheral glucose 
uptake without increasing serum insulin levels81  
However, all insulin sensitizers increase substrate 
uptake, which has implications for the formation of 
reactive oxidative species (ROS) and advanced 
glycation end-products (AGEs) and their adverse 
health effects.82, 83  Furthermore, the use of 
thiazolidinediones is considered controversial because 
of their association with significant adverse effects 
such as heart failure, fracture risks, and increased risk 
of bladder cancer.84, 85 
Metformin is the most promising (albeit 
limited) medication to manage hyperinsulinemia as it 
up-regulates GLUT4.86  However, unlike the 
thiazolidinediones, metformin also inhibits 
gluconeogenesis in the liver and/or delays glucose 
absorption from the gastrointestinal tract.87 These 
latter actions may better reduce overall glucose load 
and therefore decrease endogenous insulin secretion.  
However, emerging research suggests metformin may 
not be beneficial for treating type 2 diabetes.88  
Metformin may also cause excessive cellular nutrient 
uptake leading to increased ROS and AGEs.83 
Research does support the use of metformin for 
treating PCOS, a condition associated with 
hyperinsulinemia.86 However, pharmacological 
management of hyperinsulinemia in the absence of 
another pathology cannot be supported by the current 
literature.   
 
Novel mechanisms 
Future targets for pharmacological management of 
hyperinsulinemia may include insulin degrading 
enzyme (IDE) and the forkhead transcription factor 
(FOXA-2).  IDE mediates multiple hormones 
including insulin and glucagon.  Rodent studies 
indicate impaired IDE, with resultant hyperinsulinemia 
associated with poorer glycemic control (89).  
However, further research in this field may be able to 
selectively target glucagon.  FOXA-2 has been shown 
to improve insulin sensitivity in a number of mouse 
models by controlling key genes in fatty acid oxidation 
and glycolysis.90  
   
Concluding remarks 
Hyperinsulinemia is becoming recognised as 
an independent risk factor for chronic disease, yet 
there are few studies that address its management.  
This review evaluated hyperglycemia management 
methods, including physical activity, diet, and 
medications while focusing on the mechanisms of 
hyperinsulinemia as summarized in Table 1.  First-line 
treatment of hyperinsulinemia should encompass 
dietary and physical activity management.  Physical 
activity should include a combination of aerobic and 
resistance activities, with an emphasis on HITT.  Care 
is needed to avoid over-training, which may exacerbate 
insulin resistance.  Further research is needed to 
understand how to obtain the optimal balance.  With 
respect to diet, a carbohydrate-restricted 
Mediterranean diet theoretically confers greatest 
benefit but further research is needed, especially to 
determine to what degree carbohydrates need to be 
restricted in relation to the degree of hyperinsulinemia.  
Although metformin may up-regulate GLUT4, 
pharmacological management is not currently justified 
due to the risks of cellular nutrition overload.  Overall, 
strategies should aim to maximize participant 
adherence for greatest health benefits. 
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